

## Thrombolytic treatment of pulmonary embolism with APSAC

J. Vander Sande\*, L. Bossaert\*, M. Brochier\*\*, B. Charbonnier\*\*,  
A. Serradigmini\*\*\*, A. Elias\*\*\*, H. Pintens+, M.C. Lauwers++

*Thrombolytic treatment of pulmonary embolism with APSAC. J. Vander Sande, L. Bossaert, M. Brochier, B. Charbonnier, A. Serradigmini, A. Elias, H. Pintens, M.C. Lauwers.*

**ABSTRACT:** BRL 26921 (Eminase registered trade mark in Belgium, Germany and The Netherlands) is the p-anisoyl derivative of the primary (human) lys plasminogen-streptokinase activator complex (APSAC). The acyl-enzyme has the theoretical advantage of causing fibrinolysis *in situ* in the presence of fibrin clotbound plasminogen. It was administered to 34 patients with severe pulmonary embolism (PE) in an open multicentre study. PE was suspected on clinical, blood gas, ECG, and radiographic data. Pulmonary angiograms performed pre- and post-treatment confirmed the diagnosis and were assessed using the Miller Index (MI). Fibrinogen, plasminogen, alpha-2-antiplasmin, fibrinogen degradation products (FDP), activated partial thromboplastin time (APTT), partial thromboplastin time (PTT) were closely monitored before and after each administration of APSAC. Median angiographic improvement was 50% (range 0-94%). The following adverse events were reported: bleeding at puncture sites (n=12), haematuria (n=1), epistaxis (n=3), fever (n=2). A blood transfusion was given in one patient with an inguinal haematoma. Systemic fibrinogenolysis occurred in 20/28 patients.

*Eur Respir J., 1988, 1, 721-725.*

\* Dept of Intensive Care, University Hospital, UIA, Antwerp, Belgium.

\*\* Dept of Cardiology, CHU, Trousseau, Tours, France.

\*\*\* Dept of Cardiology, CHU, Timone, Marseille, France.

+ Beecham Pharmaceuticals, Brussels, Belgium.

++ Dept of Medicine, UIA, Antwerp, Belgium.

Correspondence: L. Bossaert, Department of Intensive Care, University Hospital Antwerp - UIA, Wilrijkstraat 10, 2520 Edegem, Belgium.

Keywords: Anisoylated plasminogen streptokinase activator complex (APSAC); fibrinolytic therapy; pulmonary embolism.

Received: August 20, 1987; accepted after revision November 23, 1987.

Severe pulmonary embolism (PE) is a frequently undiagnosed condition with a subsequent high mortality rate, ranging from 18-35% in untreated cases [1]. Early diagnosis and adequate treatment may reduce the mortality to 8% [2], whilst therapy is frequently associated with severe side effects. Before the 1970's heparin was the standard treatment, but MILLER *et al.* demonstrated that thrombolytic therapy was more effective [3]. A review of clinical trials, including the American embolism trial [4-7], confirmed this finding. A recent study demonstrated that fifteen months after thrombolytic treatment of acute massive PE, pulmonary arteriograms remained normal in 85% of the cases and the reserve capacity of the pulmonary vascular bed during heavy exercise was within normal limits [8].

Some problems associated with thrombolytic therapy remain: e.g. side-effects (systemic fibrinogenolysis, coagulation disturbances and life-threatening bleeding) [9-13], high cost, and the need for continuous infusion of unstable products with a short half-life.

The development of the acyl-enzymes was an attempt to improve the therapeutic ratio [14]. The acylation of the catalytic centre of the plasminogen-streptokinase complex leaves the lysine fibrin-binding sites free for binding to the fibrin in the thrombus [15]. After slow deacylation by hydrolysis, the active complex activates the fibrin-bound plasminogen *in situ* (fig. 1). Various

acylated molecules were studied [16, 17], and as a result of these investigations BRL 26921, the p-anisoyl derivative of the primary (human) lys plasminogen-streptokinase activator complex (APSAC) was developed. This molecule with an *in vivo* deacylation half-life of 44 min was selected for clinical studies [18-22].




Fig. 1. - Mechanism of action of acyl-enzymes.

The aim of the present open multicentre study was to evaluate the efficacy and safety of BRL 26921 in patients with massive or submassive PE.

### Patients and methods

#### Patients

Thirty four patients (19 M, 15 F) with a recent massive or submassive PE were studied. The study protocol was approved by the Hospital Ethical Committees. In table 1 patients, sex, age, dose regimens, angiographic Miller Index (before and after) are summarized. The mean age was 58 (range 25–78) yrs. In 31/34 cases diagnosis was based on initial selective pulmonary angiography.

#### Therapy protocol

All patients received up to 3 *i.v.* bolus injections of APSAC at a dose of 5 or 10 mg according to the clinical condition (table 1). Heparin was administered subsequently at a dose of 800–1,000 U·h<sup>-1</sup>. The recommended dose regimen (5 or 10 mg at 8 hourly intervals) was administered to 29 of the 34 patients. Five patients received different dosages for various reasons: 10 mg (single dose) in four patients; 5 mg+5 mg in one. In two of the four patients receiving a single dose of 10 mg a considerable fall in fibrinogen was found. In one patient the pre-existing resuscitation measures should have precluded treatment. One patient presented an epistaxis. One patient received only 2x5 mg because of the risk of bleeding from previously documented sigmoid diverticuli.

Table 1. – Patients, dose regimens, Miller Index and clinical outcome

Patient no.	Sex	Age	HR	APSAC dose mg				Angiographic Miller Index				Clinical Outcome
				Dose 1	Dose 2	Dose 3	Total	MI Before	MI After	Diff. MI	% Change (R)	
1	M	55	110	10	5	5	20	30	10	20	67	Cured
2	F	70	100	10	5	5	20	30	20	10	33	Improved
3	M	57	109	10	5	5	20	29	14	15	52	Improved
4	M	59	100	10	5	5	20	27	18	9	33	Improved
5	M	63	120	10	0	0	10	26	6	20	77	Cured
6	F	61	140	10	10	10	30	25	3	22	88	Cured
7	F	78	•	10	10	10	30	25	4	21	84	Cured
8	M	60	120	10	5	5	20	25	14	11	44	Cured
9	M	72	•	10	0	0	10	24	9	15	63	Improved
10	F	60	110	10	5	5	20	24	14	10	42	Improved
11	M	60	90	10	5	5	20	24	4	20	83	Cured
12	M	75	100	5	5	5	15	23	2	21	91	Cured
13	F	67	120	10	5	5	20	21	2	19	91	Cured
14	M	31	115	10	5	5	20	20	19	1	5	No Change
15	M	62	125	10	5	5	20	20	16	4	20	Improved
16	M	64	•	10	0	0	10	19	11	8	42	No change
17	M	68	110	5	5	5	15	19	13	6	32	Deterioration
18	M	60	120	10	5	5	20	19	16	3	16	No Change
19	M	60	136	10	5	5	20	19	10	9	47	Cured
20	F	65	70	10	5	5	20	19	15	4	21	Improved
21	F	70	140	5	5	0	10	18	5	13	72	Cured
22	M	25	128	10	5	5	20	18	9	9	50	Cured
23	M	25	88	10	5	5	20	17	5	12	71	Improved
24	F	77	80	5	5	5	15	16	1	15	94	Cured
25	F	57	120	10	5	5	20	16	16	0	0	No Change
26	F	59	60	10	5	5	20	14	11	3	21	Improved
27	F	55	80	10	5	5	20	14	6	8	57	Improved
28	F	41	•	5	5	5	15	13	2	11	85	Cured
29	M	72	45	10	10	10	30	12	3	9	75	Improved
30	F	60	150	5	5	5	15	10	9	1	10	Improved
31	F	55	•	10	5	5	20	10	5	5	50	Improved
32	M	30	135	10	10	10	30	•	•	•	•	Improved
33	M	53	78	10	10	10	30	•	•	•	•	Improved
34	F	56	128	10	0	0	10	•	•	•	•	No Change

• : missing values.

Coagulation parameters (fibrinogen, plasmin, thrombin time, APTT, alpha-2-macroglobulin, FDP, plasminogen and alpha-2-antiplasmin) were measured every 6 h during and after treatment [23-24]. Alpha-2-macroglobulin was measured using a single radial immunodiffusion assay (Behringwerke) and FDP using the Thrombo Wellcotest (Burroughs Wellcome). In some individual patients blood samples were not obtained at this exact timing to avoid interference with diagnostic or therapeutic procedures.

*Angiographic assessment*

Protocol of the pulmonary angiograms was performed independently by the investigators and the radiologist, using the Miller Index. This scoring system attributes points up to a maximum of 34 for involvement by thrombi and for the reduction of flow in the lung segments [3]. An overall score of 0/34 means a normal status, an overall score of 34 means total obstruction and no flow.

MI was measured in 31 patients before treatment. In 27 of the assessable patients the score was MI ≥ 14 (mean 21.5), indicative of a massive (MI > 18; n=22) or submassive (MI = 14-18; n=5) pulmonary embolism (table 1). Four patients had a MI between 10 and 13.

In some cases angiography was performed eight hours after each administration of APSAC to guide therapy. In all of the assessable patients final evaluation by angiography was performed between 8 and 12 h after the last administration of the drug. The percentage improvement in pulmonary circulation (R) was calculated using the following formula:

$$R\% = \frac{\text{MI before treatment} - \text{MI after treatment}}{\text{MI before treatment}} \times 100$$

**Results**

Table 1 shows the pre- and post-treatment Miller Index scores (MI). Median MI before treatment was 20 (range 10-30) and after treatment 10 (range 1-20).




Fig. 2. - Evolution of the means of MI, before and after treatment, for the three severity classes of MI defined before treatment (massive, submassive and minor). MI: miller index

Median improvement of pulmonary circulation expressed by R was 50% (range=0-94%). Figure 2 shows the evolution of the means of the Miller Index, before and after treatment, for the three severity classes of MI defined before treatment, being: minor <14, submassive 14-18 and massive >18 PE.

Coagulation parameters showed major disturbances. The most obvious of these changes were the drops in fibrinogen and plasminogen respectively, depicted in figures 3 and 4.




Fig. 3. - Mean change in fibrinogen (±2 SEM); values in percent of baseline values. The number of samples is indicated at each sampling time.




Fig. 4. - Mean change in plasminogen (±2 SEM); values in percent of baseline values. The number of samples is indicated at each sampling time.

One or more adverse events, listed in table 2 were experienced by eighteen patients. The most frequent event was bleeding at puncture sites which occurred in twelve patients; only one of these required transfusion.

One patient (no. 17) died in cardiogenic shock, caused by right ventricular myocardial infarction on day two post-treatment. A second patient (no. 19) died of septic shock on day fifteen from start of treatment; this patient

had a previous lobectomy for carcinoma and fractured ribs due to cardiopulmonary resuscitation prior to treatment, which should have excluded him from the protocol.

Table 2. - Adverse events experienced by eighteen patients

Adverse events	No. patients
Bleeding at puncture site	12*
Fever	2
Vomiting	2
Haematuria	1
Nausea, somnolence, disorientation	1
Epistaxis	3
Flush	2
Shivering	3

\*: blood transfusion required in one patient.

### Discussion

In 34 patients in the present study, 22 with massive and 5 with submassive PE treated with APSAC, a mean improvement of 50% of the MI score was demonstrated within 24-28 h of the start of treatment. This is in line with the results of the study by RUCKLEY *et al.*, where an improvement of 48% was demonstrated [25]. In nine patients with massive PE treated with APSAC, HEINRICH *et al.* reported a mean improvement of 57% after 24 h [26]. In comparison, the results obtained with urokinase and streptokinase in the UPET-study (27%) [6] and the US PAT-study (33%) [7] proved to be less satisfactory from the angiographic point of view.

The results of coagulation tests are different from the observations of PROWSE *et al.* [20] in healthy volunteers who showed no drop in fibrinogen, plasminogen or alpha-2-antiplasmin using 5 or 7 mg of APSAC. A marked drop in fibrinogen and plasminogen levels was observed in twenty patients indicating a systemic lytic state (figs 3 and 4). Although most of these patients received an initial dose of 10 mg, some presented a major drop after a starting dose of not more than 5 mg.

No apparent correlation was found between disturbances in coagulation parameters and the occurrence of major spontaneous bleeding. In spite of the marked drop in fibrinogen, only one patient required a blood transfusion because of bleeding and recovered without any ultimate adverse effects.

A further advantage of APSAC is the fact that intermittent bolus injections proved to be as satisfactory as continuous infusion of other - more unstable - products, saving much work and use of infusion pumps.

**Acknowledgements:** We wish to thank P. Vermeire, Head of the Department of Pulmonary Diseases of the University Hospital Antwerp, for critically reviewing this article.

### References

1. Barritt DW, Jordan SC. - Anticoagulant drugs in treatment of pulmonary embolism: controlled trial. *Lancet*, 1960, 1, 1309-1312.
2. Sasahara AA, Sharma GV, Barsamian EM, Schoolman M, Cella G. - Pulmonary thromboembolism: diagnosis and treatment. *J Am Med Assoc*, 1983, 249, 2945-2950.
3. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. - Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. *Br Med J*, 1971, 2, 681-692.
4. Brodgen RN, Speight TM, Avery GS. - Streptokinase: a review of its clinical pharmacology, mechanisms of action and therapeutic uses. *Drugs*, 1973, 5, 357-445.
5. The urokinase pulmonary embolism trial. A cooperative study. Phase I results. *J Am Med Assoc*, 1970, 214, 2163-2172.
6. The urokinase pulmonary embolism trial. A national cooperative study. *Circulation*, 1973, 47, Suppl II, 1-108.
7. The urokinase streptokinase embolism trial. A national cooperative study. Phase II results. *J Am Med Assoc*, 1974, 229, 1606-1613.
8. Schwartz F, Stehr H, Zimmermann R, Manthey J, Kübler W. - Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. *Circulation*, 1985, 71, 117-123.
9. Nilsson IM, Olow B. - Fibrinolysis induced by streptokinase in man. *Acta Chir Scand*, 1962, 123, 247-266.
10. Verstraete M, Vermeylen J, Schetz J. - Biochemical changes noted during intermittent administration of streptokinase. *Thrombos Haemostas*, 1978, 39, 61-68.
11. Collen D, Verstraete M. - Alpha-2-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy. *Thrombos Res*, 1979, 14, 631-639.
12. Consensus development: thrombolytic therapy in treatment: summary of an NIH Consensus Conference. *Br Med J*, 1980, 280, 1585-1587.
13. Petitpretz P, Simmoneau G, Cerrina J, Musset D, Dreyfus M, Vandebroek MD, Duroux P. - Effects of a single bolus of urokinase in patients with life-threatening pulmonary embolism: a descriptive trial. *Circulation*, 1984, 5, 861-866.
14. Collen D. - On the regulation and control of fibrinolysis. *Thrombos Haemostas*, 1980, 73, 77-93.
15. Smith RAG, Dupe RJ, English PD, Green J. - Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. *Nature*, 1981, 290, 505-507.
16. Dupe RJ, English PD, Green J, Smith RAG. - The thrombolytic activities in a rabbit model of venous thrombosis of an acyl human plasmin derivative (BRL 26920) and an acyl streptokinase-human-plasminogen activator complex (BRL 26921). *Thrombos Haemostas*, 1981, 46 (1), 211-215.
17. Smith RAG. - Acyl enzymes as fibrinolytic agents. *Thrombos Haemostas*, 1981, 46 (1), 387-394.
18. Matsuo O, Collen D, Verstraete M. - On the fibrinolytic and thrombolytic properties of active-site-p-anisoylated streptokinase-plasminogen complex (BRL 26921). *Thrombos Res*, 1981, 23, 347-358.
19. Smith RAG, Dupe RJ, English PD, Green J. - Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. *Thrombos Haemostas*, 1982, 47, 269-274.
20. Prowse CV, Dawes J, Lane DA, Ireland H, Knight I. - Proteolysis of fibrinogen in healthy volunteers following major and minor *in vivo* plasminogen activation. *Thrombos Res*, 1982, 27, 91-97.
21. Prowse CV, Hornsey V, Ruckley CV, Boulton FE. - A comparison of acylated streptokinase-plasminogen complex and

streptokinase in healthy volunteers. *Thrombos Haemostas*, 1982, 47, 132-135.

22. Staniforth DH, Smith RAG, Hibbs M. - Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers. *Eur J Clin Pharmacol*, 1983, 24, 751-756.

23. Dupe RJ, English PD, Smith RAG, Green J. - The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis. *Thrombos Haemostas*, 1981, 46, 528-534.

24. Austen DEG, Rhymes IL. - *In*: A laboratory manual of blood coagulation. Blackwell, Oxford, London, 1975.

25. Ruckley CV, Boulton FE, Buist TAS. - Acylated streptokinase complex, a new approach to thrombolytic therapy. *Br J Surg*, 1984, 71, 311-317.

26. Heinrich F, Fenn K, Zyperke G, Sporro R, Pollmann H, Hanauer G. - Therapeutische Erfahrungen mit Acyl-Streptokinase-Plasminogen-Aktivator Complex bei Lungenembolie. Proc. 3rd German-Japanese Angiology Congress, Heidelberg, 1984, 407-411.

RÉSUMÉ: BRL 26921 est le dérivé p-anisoyl du complexe activateur primaire (humain) lys plasminogène-streptokinase (APSAC). Cet enzyme acylé a l'avantage théorique de provoquer la fibrinolyse in situ en présence du plasminogène du caillot fibrineux. Il a été administré à 34 patients atteints d'embolie pulmonaire sévère dans le cadre d'une étude multicentrique ouverte. L'embolie pulmonaire a été suspectée sur la base de données cliniques, gazométriques, électrocardiographiques, et radiographiques. Les angiographies pulmonaires, réalisées avant et après le traitement, ont confirmé le diagnostic et ont été appréciées au moyen de l'Index de Miller. Le fibrinogène, le plasminogène, l'alpha-2-antiplasmin, les produits de dégradation du fibrinogène, le temps partiel de thromboplastine activée, et le temps partiel de thromboplastine, ont été suivis de près, avant et après chaque administration d'APSAC. L'amélioration angiographique médiane fut de 50% (extrêmes 0-94). Les complications suivantes ont été observées: saignement aux sites de ponction (n=12), hématurie (n=1), épistaxis (n=3), fièvre (n=2). Une transfusion sanguine a été administrée à un patient avec hématome inguinal. Une fibrinogénolyse systémique a été observée chez 20 des 28 patients.